Hillhurst Biopharmaceuticals receives NIH Heal Initiative Award for development of HBI-201 in painMichael Jaramillo2023-11-07T18:37:42+00:00November 7, 2023|
Hillhurst Biopharmaceuticals receives $3 million in NIH SBIR funding for Phase 2a clinical study in sickle cell diseaseMichael Jaramillo2023-09-21T16:57:46+00:00September 20, 2023|
Hillhurst Biopharmaceuticals announces completion of last patient last visit in Phase 1 clinical trial of HBI-002Michael Jaramillo2023-05-25T14:12:25+00:00May 23, 2023|
Hillhurst Bio Turns Gas from Poisonous to TherapeuticCeli Richardson2023-02-15T22:20:20+00:00December 5, 2022|
Hillhurst Biopharmaceuticals announces first subject dosed in Phase 1 clinical trial of HBI-002Michael Jaramillo2023-05-25T14:12:00+00:00July 26, 2022|
Deadly gas could treat diabetic blindness, according to AU studyCeli Richardson2023-02-15T22:21:18+00:00October 12, 2021|
Hillhurst Biopharmaceuticals receives NIH grant to collaborate with Massachussetts General Hospital for the development of HBI-002 for Parkinson’s diseaseMichael Jaramillo2023-11-07T18:34:54+00:00September 22, 2021|
Hillhurst Biopharmaceuticals receives funding for development of HBI-002 for the treatment of diabetic retinopathyMichael Jaramillo2023-09-21T16:53:32+00:00September 14, 2021|
Hillhurst Biopharmaceuticals Receives Study May Proceed Letter From US FDA to Initiate Phase 1 Clinical Trial of HBI-002hillhurstbio2021-09-28T02:47:40+00:00April 23, 2021|
Hillhurst Biopharmaceuticals Receives Funding For Development Of HBI-002 For Treatment of Ulcerative ColitisCeli Richardson2021-09-23T04:47:45+00:00March 25, 2021|
Hillhurst biopharmaceuticals receives funding for development of HBI-002 for prevention of anthracyline-related cardiotoxicity in cancer patientsMichael Jaramillo2023-09-21T16:56:43+00:00August 19, 2020|
Hillhurst Biopharmaceuticals Was Selected to Present at NHLBI’s Annual Sickle Cell Disease (SCD) Research Meeting 2020Celi Richardson2021-09-04T22:11:10+00:00August 12, 2020|
Hillhurst Biopharmaceuticals Receives Phase 2 SBIR Funding For Clinical Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises in Sickle Cell Disease.Celi Richardson2021-09-04T22:12:21+00:00November 28, 2018|
Hillhurst Biopharmaceuticals Receives SBIR Funding For Development Of HBI-002 For Prevention Of Delayed Graft Function In Kidney TransplantationCeli Richardson2021-09-04T22:13:22+00:00June 14, 2017|
Hillhurst Biopharmaceuticals Receives SBIR Funding For Development Of HBI-002 For Prevention Of Vaso-Occlusive Crises In Sickle Cell DiseaseCeli Richardson2021-09-04T22:14:42+00:00May 24, 2016|
Hillhurst Biopharmaceuticals Receives SBIR Funding for Development of HBI-002 as a Cytoprotective Therapeutic in Acute Cerebral InjuryCeli Richardson2021-09-23T05:16:05+00:00December 1, 2015|
Hillhurst Biopharmaceuticals Was Selected to Presented at the 7th Annual Los Angeles Venture Association (LAVA) First Look LA ConferenceCeli Richardson2021-09-09T02:30:57+00:00June 24, 2015|
Hillhurst Biopharmaceuticals Was Selected to Present Pre-Clinical Research Data at the 9th Annual Foundation for Sickle Cell Disease Research Sickle Cell Disease Research and Educational SymposiumCeli Richardson2021-09-04T22:18:01+00:00April 12, 2015|
Hillhurst Biopharmaceuticals Presented at the 6th Annual Los Angeles Venture Association (LAVA) First Look LA ConferenceCeli Richardson2021-09-04T22:18:33+00:00June 11, 2014|
